- Home
- THCH vs PLRX Comparison
THCH vs PLRX Comparison
Compare THCH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- PLRX
- Stock Information
- Founded
- THCH 2018
- PLRX 2015
- Country
- THCH China
- PLRX United States
- Employees
- THCH N/A
- PLRX N/A
- Industry
- THCH Blank Checks
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- THCH Finance
- PLRX Health Care
- Exchange
- THCH Nasdaq
- PLRX Nasdaq
- Market Cap
- THCH 84.8M
- PLRX 89.0M
- IPO Year
- THCH N/A
- PLRX 2020
- Fundamental
- Price
- THCH $2.49
- PLRX $1.72
- Analyst Decision
- THCH
- PLRX Hold
- Analyst Count
- THCH 0
- PLRX 10
- Target Price
- THCH N/A
- PLRX $3.93
- AVG Volume (30 Days)
- THCH 22.0K
- PLRX 1.0M
- Earning Date
- THCH 08-26-2025
- PLRX 11-06-2025
- Dividend Yield
- THCH N/A
- PLRX N/A
- EPS Growth
- THCH N/A
- PLRX N/A
- EPS
- THCH N/A
- PLRX N/A
- Revenue
- THCH $187,316,342.00
- PLRX N/A
- Revenue This Year
- THCH N/A
- PLRX N/A
- Revenue Next Year
- THCH N/A
- PLRX N/A
- P/E Ratio
- THCH N/A
- PLRX N/A
- Revenue Growth
- THCH N/A
- PLRX N/A
- 52 Week Low
- THCH $1.95
- PLRX $1.10
- 52 Week High
- THCH $5.15
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- THCH 39.96
- PLRX 56.68
- Support Level
- THCH $2.48
- PLRX $1.60
- Resistance Level
- THCH $2.60
- PLRX $1.89
- Average True Range (ATR)
- THCH 0.13
- PLRX 0.12
- MACD
- THCH 0.01
- PLRX 0.02
- Stochastic Oscillator
- THCH 33.70
- PLRX 66.67
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.